101 related articles for article (PubMed ID: 2885867)
21. Long term treatment of tardive dyskinesia.
Jus A; Jus K; Fontaine P
J Clin Psychiatry; 1979 Feb; 40(2):72-7. PubMed ID: 33156
[TBL] [Abstract][Full Text] [Related]
22. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
23. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum.
Boyson SJ; McGonigle P; Luthin GR; Wolfe BB; Molinoff PB
J Pharmacol Exp Ther; 1988 Mar; 244(3):987-93. PubMed ID: 2908050
[TBL] [Abstract][Full Text] [Related]
24. Results of an open phase II study with zotepine--a new neuroleptic compound.
Fleischhacker WW; Unterweger B; Barnas C; Stuppäck C; Hinterhuber H
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):64-6. PubMed ID: 2883686
[TBL] [Abstract][Full Text] [Related]
25. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients.
Coppens HJ; Slooff CJ; Paans AM; Wiegman T; Vaalburg W; Korf J
Biol Psychiatry; 1991 Apr; 29(7):629-34. PubMed ID: 1675892
[TBL] [Abstract][Full Text] [Related]
26. Blockade of hippocampal dopamine (DA) receptors: a tool for antipsychotics with low extrapyramidal side effects.
Bischoff S; Christen P; Vassout A
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(4):455-67. PubMed ID: 2900538
[TBL] [Abstract][Full Text] [Related]
27. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.
Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G
Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430
[TBL] [Abstract][Full Text] [Related]
28. An open multicentre study of the treatment of florid schizophrenia with remoxipride.
McCreadie RG; Morrison D; Eccleston D; Gall RG; Loudon J; Mitchell MJ
Acta Psychiatr Scand; 1985 Aug; 72(2):139-43. PubMed ID: 2864790
[TBL] [Abstract][Full Text] [Related]
29. Cigarette smoking and neuroleptic-induced parkinsonism.
Decina P; Caracci G; Sandik R; Berman W; Mukherjee S; Scapicchio P
Biol Psychiatry; 1990 Sep; 28(6):502-8. PubMed ID: 1977478
[TBL] [Abstract][Full Text] [Related]
30. Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients.
Robertson AG; Berry R; Meltzer HY
Psychopharmacology (Berl); 1982; 78(3):287-92. PubMed ID: 6818584
[TBL] [Abstract][Full Text] [Related]
31. Differences in [3H]-spiperone binding to peripheral blood lymphocytes from neuroleptic responsive and nonresponsive schizophrenic patients.
Grodzicki J; Pardo M; Schved G; Schlosberg A; Fuchs S; Kanety H
Biol Psychiatry; 1990 Jun; 27(12):1327-30. PubMed ID: 1973057
[No Abstract] [Full Text] [Related]
32. Do neuroleptics impair learning in schizophrenic patients?
Cutmore TR; Beninger RJ
Schizophr Res; 1990; 3(3):173-86. PubMed ID: 1980612
[TBL] [Abstract][Full Text] [Related]
33. Striatal dopamine D2 receptors in tardive dyskinesia: PET study.
Blin J; Baron JC; Cambon H; Bonnet AM; Dubois B; Loc'h C; Mazière B; Agid Y
J Neurol Neurosurg Psychiatry; 1989 Nov; 52(11):1248-52. PubMed ID: 2574230
[TBL] [Abstract][Full Text] [Related]
34. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.
Demjaha A; Murray RM; McGuire PK; Kapur S; Howes OD
Am J Psychiatry; 2012 Nov; 169(11):1203-10. PubMed ID: 23034655
[TBL] [Abstract][Full Text] [Related]
35. Neuroleptic malignant syndrome.
Pearlman C
J Clin Psychopharmacol; 1992 Apr; 12(2):144. PubMed ID: 1349308
[No Abstract] [Full Text] [Related]
36. Neuroleptic-like and antipsychotic effects of gamma-type endorphins.
Van Ree JM; Verhoeven WM; Van Praag HM; De Wied D
Mod Probl Pharmacopsychiatry; 1981; 17():266-78. PubMed ID: 6173744
[No Abstract] [Full Text] [Related]
37. Relation of plasma prolactin to clinical response in schizophrenic patients.
Gruen PG; Sachar EJ; Altman N; Langer G; Tabrizi MA; Halpern FS
Arch Gen Psychiatry; 1978 Oct; 35(10):1222-7. PubMed ID: 29592
[TBL] [Abstract][Full Text] [Related]
38. Savoxepine fails to selectively influence glucose metabolism in the rat limbic system.
Cascella NG; Tarazi FI; Shirakawa O; Tamminga CA
Psychopharmacology (Berl); 1994 Mar; 114(2):275-80. PubMed ID: 7838920
[TBL] [Abstract][Full Text] [Related]
39. Early treatment events and prediction of response to neuroleptics in schizophrenia.
Awad AG; Hogan TP
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):585-8. PubMed ID: 2868492
[TBL] [Abstract][Full Text] [Related]
40. The concept of supersensitivity psychosis.
Kirkpatrick B; Alphs L; Buchanan RW
J Nerv Ment Dis; 1992 Apr; 180(4):265-70. PubMed ID: 1348269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
